

## Strong operating performance; Maintain Buy

### Quick Note

United Phosphorus reported robust 3QFY12 earnings, with net sales up ~58% y-y, beating our and consensus estimates by a wide margin. On PAT level, results were largely in line on the back of a higher tax rate (due to a one-off impact) and higher minority interest/lower associate income. Better realisation (+8% y-y), supported by new acquisitions and INR depreciation helped company report strong numbers. Overall, these are a good set of numbers and we remain positive on the stock. We reiterate our Buy as the stock is currently trading at 7.7x our FY13F earnings estimate.

#### Key highlights

##### Strong top-line growth above expectations

- Revenues at INR19.3bn (+58% y-y and 9% q-q) was ~15-16% higher than our as well as consensus estimates of ~INR16.8-16.6bn. Better realisation (+8% y-y) plus depreciation of INR helped United Phosphorus achieve strong revenue growth. The company's business in Europe also showed resilience with 31% y-y revenue growth after it had been weak over the last two years, a positive for the stock.
- For 9MFY12, the company recorded top-line growth of 40% y-y; to achieve our target of 31.5% for FY12F, United Phosphorus only has to grow 11% y-y in 4QFY12. We believe the company will be able to achieve growth that will surpass our expectations of 31.5% y-y revenue increase.
- Revenue contribution from the acquisitions of RiceCo and DVA Agro in 3QFY12 has been ~INR3.0 bn, and hence, organic growth for the company in 3QFY12 works out to 31%, which is much higher than in the past and should be a positive for the stock.

##### Operating performance beats our estimates by 18%

- On the cost front, higher-than-expected raw material cost and employee cost was more than offset by the decline in other manufacturing expense. This led to EBITDA margin of 18.1% higher than our expectation of 17.6%. The slight slippage in the EBITDA margin on a sequential basis (18.1% vs. 18.3% in 2QFY12) was on account of higher employee cost. Depreciation in INR against various currencies was the primary reason for this increase.
- Higher revenue coupled with slightly better-than-expected margin resulted in **EBITDA at INR3.5bn (+57% y-y and 7% q-q), which beat our as well as consensus expectations by 18% and 9%, respectively.**
- On sequential basis, interest and financial costs was down 57% to INR826mn because the company has recognized a MTM loss of INR1.1bn on account of foreign currency debt in the last quarter. Although some of these losses were reversed as the company realised gains on hedging derivatives it has used on foreign debt but

January 30, 2012

<b>Rating</b> Remains	<b>Buy</b>
<b>Target price</b> Remains	INR 205
<b>Closing price</b> January 30, 2012	INR 144

#### Research analysts

##### India Agri-Related

**Aatash Shah - NFASL**  
[aatash.shah@nomura.com](mailto:aatash.shah@nomura.com)  
+91 22 4037 4194

**Vineet Verma - NSFSP**  
[vineet.verma@nomura.com](mailto:vineet.verma@nomura.com)  
+91 22 4037 4487

See Appendix A-1 for analyst certification, important disclosures and the status of non-US analysts.

these gains were more or less offset by forex loss on account of rupee depreciation in the reported quarter.

- At the operating level, the company's performance exceeded our as well as the Street's expectations. However, on the bottom line, adjusted PAT (forex loss and tax benefit from the forex loss) at INR1.1bn was largely in line with our expectations due to the higher tax rate and higher minority interest / lower associate income. The effective tax rate at ~32% was a result of amalgamation of 100% United Phosphorus' Mauritius subsidiary into a stand-alone India entity. The company has guided for an effective tax rate in the range of 23-25%.

## Takeaways from management's call

- Management remained confident that the company would be able to achieve a revenue growth of 30-35% for FY12F, which should be driven by a Brazilian acquisition in 4QFY12 due to the seasonally strong quarter in Latin America. The weaker 15% y-y growth in 3QFY12 for India business was on the back of challenging weather conditions in Southern India, particularly Andhra Pradesh. In the short term, management sees some headwinds due to continuing challenging conditions in AP.
- The company continues to expect to generate a PBDIT margin to the tune of 19-20% in FY12F. Any volatility in raw material prices can lead to slippage in margins as cost increases can only be passed on to its customers with a lag.
- New acquisitions have resulted in margins turning out to be lower than earlier, and management believes that it will take another 3-4 quarters to bring them back to earlier levels. Specifically, DVA Agro, which was acquired by the company in July 2011 has a gross margin ranging between ~28-30%, ie, lower than the company's overall gross margin of around ~46%. Sipcam UPL Brasil, in which the company picked 50% stake in April 11 recorded a loss of INR 110mn (propionate share) in 2QFY12. Management expects a total loss of ~INR300mn on full year basis from Sipacam UPL Brasil.
- The performance of European business has showed resilience after UNTP's post-harvest treatment product, Decco, was restricted in EU after May 2010. Management indicated that the increase in its average realisation from the European market has been higher than its overall 8% y-y increase.
- On the working capital front, the increase in the no. of inventory days to 99 days from 86 days in the last quarter was partly attributable to inventory restocking due to upcoming crop season (Feb-July) in North America and European markets.
- On the balance sheet side, the company's average cost of debt continues to be in the range of 7-8% on a consolidated basis and the company an outstanding net debt of around INR 25bn (as of Dec-11).
- South America has experienced a weather disturbance known as La Niña but as of now the impact from this seen is seen to be minimal.

Fig. 1: Snapshot of 3QFY12 results (INR mn)

(INR. mn)	3QFY12A	3QFY12E (Nomura estimates)	2QFY12A	QoQ growth (%)	3QFY11A	YoY growth (%)
<b>Net Sales</b>	<b>19,288</b>	<b>16,781</b>	<b>17,757</b>	9%	<b>12,221</b>	58%
<b>Raw material costs</b>	<b>10,305</b>	<b>8,772</b>	<b>9,700</b>	6%	<b>5,695</b>	81%
% of net sales	53.4%	52.3%	54.6%		46.6%	
<b>Employee costs</b>	<b>1,948</b>	<b>1,650</b>	<b>1,511</b>	29%	<b>1,298</b>	50%
% of net sales	10.1%	9.8%	8.5%		10.6%	
<b>Other expenses</b>	<b>3,551</b>	<b>3,413</b>	<b>3,291</b>	8%	<b>3,014</b>	18%
% of net sales	18.4%	20.3%	18.5%		24.7%	
<b>Total expenses</b>	<b>15,804</b>	<b>13,835</b>	<b>14,502</b>	9%	<b>10,007</b>	58%
<b>EBIDTA</b>	<b>3,484</b>	<b>2,947</b>	<b>3,255</b>	7%	<b>2,215</b>	57%
Other income	107	140	196	-45%	262	-59%
<b>PBIDT</b>	<b>3,590</b>	<b>3,086</b>	<b>3,451</b>	4%	<b>2,477</b>	45%
Depreciation	785	700	719	9%	491	60%
Interest	826	800	1,918	-57%	893	-7%
<b>PBT</b>	<b>1,979</b>	<b>1,587</b>	<b>814</b>	143%	<b>1,093</b>	81%
Tax	626	579	151	315%	266	135%
<b>PAT</b>	<b>1,353</b>	<b>1,007</b>	<b>663</b>	104%	<b>827</b>	64%
Minority loss/(profit)	216	(40)	(51)	-527%	(12)	-1854%
Extraordinary profit/(loss)	(13)	800	(144)		-	
<b>Reported PAT</b>	<b>1,124</b>	<b>1,847</b>	<b>570</b>	97%	<b>839</b>	34%
<b>Adjusted PAT</b>	<b>1,124</b>	<b>1,191</b>				
EBIDTA margins (%)	18.1%	17.6%	18.3%	0%	18.1%	
PBIDT margins (%)	18.5%	18.2%	19.2%	-1%	19.8%	

Source: Company data, Nomura estimates

Fig. 2: Geographical breakdown (in INR mn)

	3QFY11	4QFY11	1QFY12	2QFY12	3QFY12
North America	2,220	4,100	5,110	2,990	3590
India	3,320	3,030	5,360	5,690	3810
Europe	2,020	4,490	3,760	2,230	2650
Rest of World	4,920	7,200	4,620	7,040	9340
<b>Total</b>	<b>12,480</b>	<b>18,820</b>	<b>18,850</b>	<b>17,950</b>	<b>19,390</b>
<b>(y-y)% growth</b>	<b>3QFY11</b>	<b>4QFY11</b>	<b>1QFY12</b>	<b>2QFY12</b>	<b>3QFY12</b>
North America	21%	25%	32%	13%	62%
India	6%	48%	32%	25%	15%
Europe	-24%	-17%	3%	8%	31%
Rest of World	25%	58%	39%	98%	90%
<b>Total</b>	<b>8%</b>	<b>23%</b>	<b>27%</b>	<b>40%</b>	<b>55%</b>

Source: Company data

Fig. 3: Sale variance breakup

	3QFY11	4QFY11	1QFY12	2QFY12	3QFY12
Exchange impact	-5%	1%	1%	5%	19%
Rate variance	-3%	3%	1%	4%	8%
Quantity variance	14%	20%	25%	31%	31%
<b>Total</b>	<b>6%</b>	<b>24%</b>	<b>27%</b>	<b>40%</b>	<b>58%</b>

Source: Company data

# Appendix A-1

## Analyst Certification

We, Aatash Shah and Vineet Verma, hereby certify (1) that the views expressed in this Research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of our compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

## Issuer Specific Regulatory Disclosures Mentioned companies


Issuer name	Ticker	Price	Price date	Stock rating	Sector rating	Disclosures
United Phosphorus	UNTP IN	INR 144	30-1-2012	Buy	Not rated	

## Previous Rating

Issuer name	Previous Rating	Date of change
United Phosphorus	Not Rated	16-7-2009

### United Phosphorus (UNTP IN) INR 144 (30-1-2012) Buy (Sector rating: Not rated)

Rating and target price chart (three year history)



For explanation of ratings refer to the stock rating keys located after chart(s)

**Valuation Methodology** In valuing UNTP, we apply a 10% discount to the stock's six-year historical average rolling forward P/E multiple of 11.2x to our one-year rolling forward EPS forecast (INR20.5). Our target price is INR205.

**Risks that may impede the achievement of the target price** Downside risks include: 1) a fall in crop prices and de-stocking of inventory, which may lead to lower demand for crop-protection chemicals; 2) an increase in raw material prices, which could hit margins; 3) changes in approval regulations; 4) a fluctuation in forex rates; 5) expensive future acquisitions; and 6) inconducive weather patterns for agriculture.

## Important Disclosures

### Online availability of research and conflict-of-interest disclosures

Nomura research is available on [www.nomuranow.com](http://www.nomuranow.com), Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne.

Important disclosures may be read at <http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx/> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email [grpsupport-eu@nomura.com](mailto:grpsupport-eu@nomura.com) for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

*Industry Specialists* identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have coverage. *Industry Specialists* do not contribute in any manner to the content of research reports in which their names appear. *Marketing Analysts* identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura's Equity Research product in the sector for which they have coverage. *Marketing Analysts* may also contribute to research reports in which their names appear and publish research on their sector.

### Distribution of ratings (US)

The distribution of all ratings published by Nomura US Equity Research is as follows:

35% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 11% of companies with this rating are investment banking clients of the Nomura Group\*.

59% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 2% of companies with this rating are investment banking clients of the Nomura Group\*.

6% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 0% of companies with this rating are investment banking clients of the Nomura Group\*.

As at 31 December 2011. \*The Nomura Group as defined in the Disclaimer section at the end of this report.

### Distribution of ratings (Global)

The distribution of all ratings published by Nomura Global Equity Research is as follows:

47% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 40% of companies with this rating are investment banking clients of the Nomura Group\*.

43% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 45% of companies with this rating are investment banking clients of the Nomura Group\*.

10% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 21% of companies with this rating are investment banking clients of the Nomura Group\*.

As at 31 December 2011. \*The Nomura Group as defined in the Disclaimer section at the end of this report.

### Explanation of Nomura's equity research rating system in Europe, Middle East and Africa, US and Latin America

The rating system is a relative system indicating expected performance against a specific benchmark identified for each individual stock. Analysts may also indicate absolute upside to target price defined as (fair value - current price)/current price, subject to limited management discretion. In most cases, the fair value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as discounted cash flow or multiple analysis, etc.

### STOCKS

A rating of '**Buy**', indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of '**Neutral**', indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of '**Reduce**', indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of '**Suspended**', indicates that the rating, target price and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including, but not limited to, when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the company.

Benchmarks are as follows: **United States/Europe**: Please see valuation methodologies for explanations of relevant benchmarks for stocks (accessible through the left hand side of the Nomura Disclosure web page: <http://go.nomuranow.com/research/globalresearchportal/>); **Global Emerging Markets (ex-Asia)**: MSCI Emerging Markets ex-Asia, unless otherwise stated in the valuation methodology.

### SECTORS

A '**Bullish**' stance, indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months. A '**Neutral**' stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months. A '**Bearish**' stance, indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months.

Benchmarks are as follows: **United States**: S&P 500; **Europe**: Dow Jones STOXX 600; **Global Emerging Markets (ex-Asia)**: MSCI Emerging Markets ex-Asia.

### Explanation of Nomura's equity research rating system in Japan and Asia ex-Japan

#### STOCKS

Stock recommendations are based on absolute valuation upside (downside), which is defined as (Target Price - Current Price) / Current Price, subject to limited management discretion. In most cases, the Target Price will equal the analyst's 12-month intrinsic valuation of the stock, based on an appropriate valuation methodology such as discounted cash flow, multiple analysis, etc.

A '**Buy**' recommendation indicates that potential upside is 15% or more. A '**Neutral**' recommendation indicates that potential upside is less than 15% or downside is less than 5%. A '**Reduce**' recommendation indicates that potential downside is 5% or more. A rating of '**Suspended**' indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company.

Securities and/or companies that are labelled as '**Not rated**' or shown as '**No rating**' are not in regular research coverage of the Nomura entity identified in the top banner. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies.

### SECTORS

A '**Bullish**' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation. A '**Neutral**' rating means most stocks in the sector have (or the weighted average recommendation of the stocks

under coverage is) a neutral absolute recommendation. A '**Bearish**' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation.

### **Target Price**

A Target Price, if discussed, reflect in part the analyst's estimates for the company's earnings. The achievement of any target price may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market, and may not occur if the company's earnings differ from estimates.

## Disclaimers

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. Affiliates and subsidiaries of Nomura Holdings, Inc. (collectively, the 'Nomura Group'), include: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('Nipic'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ('NIHK'), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ('NFIK'), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at <http://dis.kofia.or.kr>); Nomura Singapore Ltd. ('NSL'), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Capital Nomura Securities Public Company Limited ('CNS'), Thailand; Nomura Australia Ltd. ('NAL'), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412; P. T. Nomura Indonesia ('PTNI'), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ('NSM'), Malaysia; Nomura International (Hong Kong) Ltd., Taipei Branch ('NITB'), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ('NFASL'), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, MCX: INE261299034); Banque Nomura France ('BNF'), regulated by the Autorité des marchés financiers and the Autorité de Contrôle Prudentiel; Nipic, Dubai Branch ('Nipic, Dubai'); Nipic, Madrid Branch ('Nipic, Madrid') and Nipic, Italian Branch ('Nipic, Italy').

This material is: (i) for your private information, and we are not soliciting any action based upon it; (ii) not to be construed as an offer to sell or a solicitation of an offer to buy any security in any jurisdiction where such offer or solicitation would be illegal; and (iii) based upon information from sources that we consider reliable, but has not been independently verified by Nomura Group.

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information.

Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document. Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice.

Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (as defined within Financial Services Authority ('FSA') rules in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of MSCI Inc. ('MSCI'). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates. Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns.

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment. The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction.

This document has been approved for distribution in the UK and European Economic Area as investment research by Nipic, which is authorized and regulated by the FSA and is a member of the London Stock Exchange. It does not constitute a personal recommendation, as defined by the FSA, or take into account the particular investment objectives, financial situations, or needs of individual investors. It is intended only for investors who are 'eligible counterparties' or 'professional clients' as defined by the FSA, and may not, therefore, be redistributed to retail clients as defined by the FSA. This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934.

This document has not been approved for distribution in the Kingdom of Saudi Arabia ('Saudi Arabia') or to clients other than 'professional clients' in the United Arab Emirates ('UAE') by Nomura Saudi Arabia, Nipic or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or to any person located in Saudi Arabia or to clients other than 'professional clients' in the UAE. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are a 'professional client' in the UAE and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of Saudi Arabia or the UAE.

**NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP.** Further information on any of the securities mentioned herein may be obtained upon request. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

Additional information is available upon request. Disclosure information is available at the Nomura Disclosure web page: <http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx>